The stock of Zai Lab Limited ADR (ZLAB) has seen a 3.20% increase in the past week, with a -0.27% drop in the past month, and a -0.23% decrease in the past quarter. The volatility ratio for the week is 5.51%, and the volatility levels for the past 30 days are at 4.65% for ZLAB. The simple moving average for the past 20 days is 1.29% for ZLAB’s stock, with a 20.39% simple moving average for the past 200 days.
Is It Worth Investing in Zai Lab Limited ADR (NASDAQ: ZLAB) Right Now?
Moreover, the 36-month beta value for ZLAB is 1.02. Analysts have varying opinions on the stock, with 8 analysts rating it as a “buy,” 3 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ZLAB is 108.70M and currently, short sellers hold a 5.46% of that float. On January 17, 2025, ZLAB’s average trading volume was 924.98K shares.
ZLAB) stock’s latest price update
Zai Lab Limited ADR (NASDAQ: ZLAB)’s stock price has plunge by 2.88relation to previous closing price of 25.38. Nevertheless, the company has seen a 3.20% surge in its stock price over the last five trading sessions. businesswire.com reported 2025-01-17 that SHANGHAI & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for KarXT for the treatment of schizophrenia in adults. “There are more than 8 million patients living with schizophrenia in China who face significant unmet needs due to the limited efficacy and undesirable side effects of current treatment options,” said Dr. Rafael Amado, M.D., Presiden.
Analysts’ Opinion of ZLAB
Many brokerage firms have already submitted their reports for ZLAB stocks, with Morgan Stanley repeating the rating for ZLAB by listing it as a “Overweight.” The predicted price for ZLAB in the upcoming period, according to Morgan Stanley is $47.50 based on the research report published on December 14, 2023 of the previous year 2023.
Cantor Fitzgerald, on the other hand, stated in their research note that they expect to see ZLAB reach a price target of $70. The rating they have provided for ZLAB stocks is “Overweight” according to the report published on August 10th, 2023.
Macquarie gave a rating of “Outperform” to ZLAB, setting the target price at $64 in the report published on January 21st of the previous year.
ZLAB Trading at -3.86% from the 50-Day Moving Average
After a stumble in the market that brought ZLAB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -28.66% of loss for the given period.
Volatility was left at 4.65%, however, over the last 30 days, the volatility rate increased by 5.51%, as shares sank -3.21% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -15.49% lower at present.
During the last 5 trading sessions, ZLAB rose by +3.18%, which changed the moving average for the period of 200-days by +62.75% in comparison to the 20-day moving average, which settled at $25.78. In addition, Zai Lab Limited ADR saw -0.31% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ZLAB starting from Chen Kai-Xian, who sale 7,750 shares at the price of $17.22 back on Jul 01 ’24. After this action, Chen Kai-Xian now owns 60,778 shares of Zai Lab Limited ADR, valued at $133,455 using the latest closing price.
Amado Rafael sale 7,583 shares at $26.28 during a trade that took place back on Dec 31 ’24, which means that Amado Rafael is holding 33,834 shares at $199,289 based on the most recent closing price.
Stock Fundamentals for ZLAB
Current profitability levels for the company are sitting at:
- -0.95 for the present operating margin
- 0.63 for the gross margin
The net margin for Zai Lab Limited ADR stands at -0.76. The total capital return value is set at -0.48. Equity return is now at value -34.98, with -26.70 for asset returns.
Based on Zai Lab Limited ADR (ZLAB), the company’s capital structure generated 0.16 points at debt to capital in total, while cash flow to debt ratio is standing at -1.38. The debt to equity ratio resting at 0.19. The interest coverage ratio of the stock is -250.52.
Currently, EBITDA for the company is -367.54 million with net debt to EBITDA at 1.72. When we switch over and look at the enterprise to sales, we see a ratio of 6.65. The receivables turnover for the company is 5.14for trailing twelve months and the total asset turnover is 0.36. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.01.
Conclusion
To wrap up, the performance of Zai Lab Limited ADR (ZLAB) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
